2019 was a year of activism, shifts in political ideology, and tech innovation, all resulting in a pause for reflection on how we interact with our planet, one another and technology.
At FDNA, we found ourselves amidst, and on-track with, the seemingly daily advancements in the health and technology sphere. Our small (but mighty!) team worked tirelessly in 2019, closing out the year and decade one step closer to our ultimate goal: ending the diagnostic journey for those living with rare genetic disease. With the help of our existing global network of healthcare professionals, in addition to 25,300 new users of Face2Gene, we were able to impact the lives of 158,595 new patients this year.
From forging innovative partnerships to launching cutting edge AI-based technologies, here are some of our highlights from 2019:
- Launched Face2Gene LABS, a new and exciting product that significantly improves the diagnostic efficiency and accuracy of NGS
- Entered into a strategic partnership with PerkinElmer Genomics, the first global genetic testing lab to fully integrate next-generation phenotyping into their genetic analysis workflow
- Pioneered an innovative path for rare disease clinical trial recruitment in collaboration with Covance
- Co-authored 15 new peer-reviewed publications in high-impact scientific journals supporting our NGP technology as a gold standard in clinical genetics, including:
- Identifying facial phenotypes of genetic disorders using deep learning, Nature Medicine
- PEDIA: prioritization of exome data by image analysis, Genetics in Medicine
- Continued to advocate for ethical use of AI in healthcare, including a featured talk at HLTH 2019
- Recognized as an opinion leader in the field of AI and facial analysis in healthcare by 500+ news publications, including the Wall Street Journal, Science Magazine, Forbes and more
As we step into 2020, we are staying ahead of the curve when it comes to healthcare and technology trends, and how FDNA’s mission fits into this ever-evolving landscape. With AI-supported diagnosis through medical imaging, mainstream genome analysis and a call for more responsible monitoring of technology on the rise, we are primed to meet the challenges this next year, decade, and chapter of innovation has in store. 2020 is poised to take us even closer in bringing genetics to the forefront of mainstream medicine.
If you are interested in learning more about how to be part of our journey, please reach out to info@fdna.com.